By 10 years, 33% of cases with high levels of both TNFRSF9 and PTN died of prostate cancer compared to only 5% of cases with low levels of one or both of these proteins (Fig. 7c), highlighting the utility of these blood markers for risk stratification of AA prostate cancer patients. This evidence concerns the gene TNFRSF9 and prostate carcinoma.